References


  1. Mandayam S, Shahinian VB. Are chronic dialysis patients at increased risk for cancer? J Nephrol 2008;21:166-174. 

  2. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80: S254-S264.

  3. Birkelan SA, Løkkegaard H, Storm HH: Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000;355:1886-1887.

  4. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol 2000;27:115-123. 

  5. Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of renal cell carcinoma. Eur Urol 2011;60:615-621. 

  6. Russo P. Renal cell carcinoma: Presentation, staging, and surgical treatment. Semin Oncol 2000;27:160-176. 

  7. Lipworth L, McLaughlin JK, Tarone RE, Blot WJ. Renal cancer paradox: higher incidence but not higher mortality among African-Americans. Eur J Cancer Prev 2011;20:331-333. 

  8. Russo P, Jang T, Eggener S, et al. Survival rates after resection for localized kidney cancer 1989-2004. Cancer 2008;113(1):84-96. 

  9. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell. 
J Urol 2001; 166:63-67. 

  10. Russo P. Partial nephrectomy for renal cancer: Part 1. BJU Int 2010;105:1206-1220. 

  11. Teloken PE, Thompson RH, Tickoo SK, et al. Prognostic impact of histological subtype in patients with surgically treated localized renal cell carcinoma. 
J Urol 2009;182:2132-2136. 

  12. Algaba F, Akaza H, López-Beltrán A, et al. Current pathology keys of renal cell carcinoma. Eur Urol 2011;60:634-643. 

  13. Matas AJ, Simmons RL, Kjellstrand CM, et al. Increased incidence of malignancy during chronic renal failure. Lancet 1975;1:883-886. 

  14. Cengiz, K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002;33:121-126. 

  15. Stewart JH, Vajdoc CM, van Leeuwen MT, et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 2009;10:3225-3231.

  16. Liang JA, Sun LM, Yeh JJ, et al. The association between malignancy and end stage renal disease in Taiwan. Jpn J Clin Oncol 2011;41:752-757. 

  17. Lee JE, Han SH, Cho BC, et al. Cancer in 
patients on chronic dialysis. J Korean Med Sci 2009;41:S95-S101.

  18. Mosconi G, Stalterii L, Centofanti F, et al. Incidence of cancer in kidney transplantation waiting list patients: a single center experience. Transplant Proc 2011;43:1003-1005.

  19. Tickoo SK, DePerolta-Venturia MN, Harik LR. Worcester neoplasms in end stage renal disease: An experience from 66 tumor-bearing kidneys with emphasis on histological patterns distinct from those in sporadic adult renal neoplasms. Am J Surg Path 2006;30:141-153.

  20. Ishikawa I, Kovacs G. High incidence of papillary renal cell tumors in patients on chronic haemodialysis. Histopathology 1993;22:135-139. 

  21. Neuzillett Y, Mathieu R, Long JA, et al. Renal cell carcinoma (RCC) in patients with end stage renal disease exhibits many favorourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol 2011;60:366-373. 

  22. Hora M, Hes O, Reischig T, et al. Tumours in end-stage kidney. Transplant Proc 2008;10:3354-3358.

  23. Hajj P, Ferlicot S, Massoud W, et al. Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Urology 2009;74:631-634.

  24. Nouth MA, Kuroda N, Yamashita M, et al. Renal cell carcinoma in patients with end stage renal disease: relationship between histological type and duration of dialysis. BJU Int 2010;105:620-627. 

  25. Suson KD, Sausville JE, Sener A, Phelan MW. Native nephrectomy for renal cell carcinoma in transplant recipients. Transplantation 2011;91:1376-1379. 

  26. Sarnak M, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for the development of cardiovascular disease: a statement from the American Heart Association Council on Kidney in Cardiovascular Disease. High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169. 

  27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on TN Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572-2589. 

  28. Levey AS, Coresh J, Bolton K, et al. Kidney Disease Outcome Quality Initiative. K/DOQI clinical guideline for chronic kidney disease evaluation, classification, stratification. Am. J. Kidney Dis 2002;40:E19-E22.

  29. Ritz E, McClellan WW. Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. 
J Am Soc Nephrol 2004;15:513-516. 

  30. Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease. JAMA 2005;293:1737-1745.

  31. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047. 

  32. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010;268:456-467. 

  33. Go AS, Chertow GM, Fan D, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;35:112-196. 

  34. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES 3 study. Mayo Clin Proc 2005;80:1270-1277. 

  35. Stevens LA, Li S, Wang C, et al. Prevalence of CKD and comorbid illness in elderly patients in the United State: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010;55:S23-S33. 

  36. Weng PH, Hung KY, Huang HL, et al. Cancer-specific mortality in chronic kidney disease: longitudinal follow up of a large cohort. Clin J Am Soc Nephrol 2011;6:1121-1128. 

  37. Wong G, Hayen A, Chapman JR, et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009;20:1341-1350.

  38. Launay-Vacker V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anti cancer drug management. The renal insufficiency and anticancer medications study (IRMA). Cancer 2007;110:1376-1384.

  39. Canter D, Kutikov A, Sirohi M, et al. Prevalence of baseline CKD in patients presenting with solid renal tumors. Urology 2011; 77:781-785. 

  40. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumors: a retrospective cohort study. Lancet Oncol 2006;7:735-740. 

  41. Goh A, Vathsala A. Re: native renal cysts and dialysis duration are risk factors for renal cell carcinoma in renal transplant recipients. Am J Transplant 2011;11:86-92.

  42. Bijol V, Mendez GP, Huwitz S, et al. Evaluation of the nonneoplastic pathology in tumor nephrectomy specimens. Am J Surg Pathol 2006;30:575-584.

  43. Henriksen KJ, Meehan SM, Chang A. Nonneoplastic kidney diseases in adult tumor nephrectomy and nephroureterectomy specimens: common, harmful, yet underappreciated. Arch Pathol Lab Med 2009;133:1012-1025. 

  44. Bonsib SM, Pei Y. The non-neoplastic kidney in tumor nephrectomy specimens: what can it show and what is important? Adv Anat Pathol 2010;4:235-250.

  45. Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol 2010;23:253-262. 

  46. Dou L, Cerini C, Brunet P, et al. P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 2002;62;1999-2009. 

  47. Faure V, Cerini C, Paul P, et al. The uremic solute p-cresol decreases leukocyte transendothelial migration in vitro, Int Immunol 2006;18:1453-1459.

  48. Russo P. Open radical nephrectomy for localized renal cell carcinoma. In: Vogelzang, Nicholas J. Genitourinary Oncology. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2006:725-731. 

  49. Russo P. The role of surgery in the management of early-stage renal cancer. Hematol Oncol Clin North Am. 2011;25:737-52.

  50. Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 503: 959-966, 2010. 

  51. Fehrman-Ekholm I, Duner F, Brink B, et al. No evidence of loss of kidney function in living kidney donors from 
cross sectional follow up. Transplantation 2001;
72:444-449. 

  52. Goldfarb DA, Matin SF, Braun WE, et al: Renal outcome 25 years after donor nephrectomy. J Urol 2001;166:2043-2051. 

  53. Kaplan C, Pasternack B, Shah H, et al. Age-related incidence of sclerotic glomeruli in human kidneys. Am J Pathol 1975;80:227-235. 

  54. Lau WK, Blute ML, Weaver AL, et al. Matched comparison of radical nephrectomy vs. nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contra lateral kidney. Mayo Clinic Proc 2000;75:1236-1242. 

  55. McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology 2002;59:816-820. 

  56. Thompson HR, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared to partial nephrectomy. J Urol 2008;179:468-473. 

  57. Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes. J Urol 2009;181:55-62. 

  58. Tan HJ, Norton EC, Ye Z, et al. Long-term survival following partial vs. radical nephrectomy among older patients with early-stage kidney cancer. JAMA 2012;207:1629-1635. 

  59. Kim SP, Thompson H, Boorjian SA, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: A systematic review and meta-analysis. 
J Urology 2012;188:51-57.

  60. Foyil KV, Ames CD, Ferguson GG, et al. Long-term changes in creatinine clearance after laparoscopic renal surgery. J Am Coll Surg 2008;206:511-515. 

  61. Lane BR, Poggio ED, Herts BR, et al. Renal function assessment in the era of chronic kidney disease: 
Renewed emphasis on renal function centered patient care. J Urol 2009;182:436-444. 

  62. Campbell SC, Novick, AC, Belldegrun A, et al. Guideline for Management of the Clinical T1 Renal Mass. 
J Urol 2009;182:1271-1279. 

  63. Hollenback BK, Tash DA, Miller DC, et al: National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology 2006;67:254-259. 

  64. Miller DC, Hollingsworth JM, Hafez KS, et al: Partial nephrectomy for small renal masses. An emerging quality of care concern? J Urol 2006;175:853-857. 

  65. Dulabon LM, Lowrance WT, Russo P, Huang WC. Trends in Renal Tumor Surgery Delivery within the United States. Cancer 2010;116:2316-2321.


From the January 01, 2013 Issue of Renal and Urology News

Topics:

Chronic Kidney Disease CKD End-Stage Renal Disease Kidney Cancer